WuXi Biologics partners with HanchorBio on next-gen immunotherapies
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
List view / Grid view
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
Novel approach holds potential to reduce the industry’s dependence on coconut and palm oil extraction for bioproduction of short- and medium-chain fatty acids.
As vaccines are buffeted by political pressures, the CDMO discussed its growth approach and some of its key collaborations.
Named CEO of the Year at CPHI Frankfurt, the CDMO's head talks about the type of company he and his team are building.
Digital twin model offers potential for advanced control during continuous pharmaceutical manufacturing processes.
The new Winter Park plant advances the pharma company’s $23 billion commitment to enhance its US radioligand medicine manufacturing capabilities.
The quality control (QC) standards publication sets animal-free bacterial endotoxins testing (BET) as the new norm in Europe.
The CDMO will acquire the pharma company’s Human Genome Sciences facility in Maryland.
News organisation ProPublica’s Rx Inspector tool connects FDA information on factory location and regulatory records to individual generic drugs.
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
UK biotech commits to scale up of 228Th extraction and a long-term supply agreement to facilitate production of thousands of doses of 212Pb for cancer therapies annually.
Announcement of Eli Lilly and Company's fourth new US manufacturing plant is expected within the next few weeks.
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.